Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 4/2002

01-04-2002 | Review Article

Pharmacological Treatment of Psychosis and Agitation in Elderly Patients with Dementia

Four Decades of Experience

Authors: Sandra S. Kindermann, Christian R. Dolder, Anne Bailey, Ira R. Katz, Professor Dilip V. Jeste

Published in: Drugs & Aging | Issue 4/2002

Login to get access

Abstract

A number of studies, using different research designs and assessment instruments, have been conducted to elucidate the differential effects of drug treatments for psychosis, agitation and aggression in elderly patients with dementia. We have reviewed literature published from 1960 to 2000 on this topic; 48 studies that met our selection criteria were identified from Medline and Science Citation Index.
Antipsychotic medication was generally effective for the treatment of psychosis and agitation in elderly patients with dementia. In double-blind, placebo-controlled trials in this population, mean improvement rates were 61% with antipsychotic s and 35% with placebo. Atypical antipsychotics appeared promising, but the number of well-designed studies has been small so far. Methodological limitations of the studies reviewed are discussed; future trials should ensure adequate sample size and duration and involve direct comparisons of individual medications.
In conclusion, conventional antipsychotics are modestly effective for treatment of psychosis and agitation in elderly individuals with dementia, whereas newer treatments such as atypical antipsychotics appear to be at least as effective while having fewer adverse effects. Nonetheless, there is no currently available ideal pharmacotherapy, and psychosocial management is a necessary part of overall treatment. Additional large-scale, well-controlled studies are needed before conclusive statements regarding the value of treatment of psychosis and agitation with atypical antipsychotics and non-antipsychotic agents can be made.
Literature
1.
Raskind MA, Risse SC. Antipsychotic drugs and the elderly. J Clin Psychiatry 1986; 47: 17–22PubMed
2.
Evans DA, Funkenstein H, Albert MS, et al. Prevalence of Alzheimer’s disease in a community population of older persons: higher than previously reported. JAMA 1989; 262: 2551–6PubMedCrossRef
3.
Bachman DL, Wolf PA, Linn R, et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham study. Neurology 1992; 42: 115–9PubMedCrossRef
4.
Cummings JL, Jeste DV. Alzheimer’s disease and its management in the year 2010. Psychiatr Serv 1999; 50: 1173–7PubMed
5.
Wragg RE, Jeste DV. Neuroleptics and alternative treatments: management of behavioral symptoms and psychosis in Alzheimer’s disease and related conditions. Psychiatr Clin North Am 1988; 11: 195–214PubMed
6.
Paulsen JS, Salmon DP, Thai LJ, et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology 2000; 54: 1965–71PubMedCrossRef
7.
Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38: 553–63PubMed
8.
Jeste DV, Rockwell E, Harris MJ, et al. Conventional vs newer antipsychotics in elderly patients. Am J Geriatr Psychiatry 1999; 7: 70–6PubMed
9.
Christensen DB, Benfield WR. Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients. J Am Geriatr Soc 1998; 46: 620–5PubMed
10.
Gleason RP, Schneider LS. Carbamazepine treatment of agitation in Alzheimer’s outpatients refractory to neuroleptics. J Clin Psychiatry 1990; 51: 115–8PubMed
11.
Tariot P, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155: 54–61PubMed
12.
Pollock BG, Mulsant BH, Sweet R, et al. An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations. Am J Geriatr Psychiatry 1997; 5: 70–8PubMed
13.
Cummings JL, Gorman DG, Shapira J. Physostigmine ameliorates the delusions of Alzheimer’s disease. Biol Psychiatry 1993; 33: 536–41PubMedCrossRef
14.
Sultzer DL, Gray KF, Gunay I, et al. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry 1997; 5: 6–69
15.
Kunik ME, Puryear L, Orengo CA, et al. The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances. Int J Geriatr Psychiatry 1998; 13: 29–34PubMedCrossRef
16.
Lott AD, McElroy SL, Keys MA. Valproate in the treatment of behavioral agitation in the elderly patients with dementia. J Neuropsychiatry Clin Neurosci 1995; 7: 314–9PubMed
17.
Sandborn WD, Bendfeldt F, Hamdy R. Valproic acid for physically aggressive behavior in geriatric patients. Am J Geriatr Psychiatry 1995; 3(3): 239–42CrossRef
18.
Cummings JL, Donohue JA, Brooks RL. The relationship between donepezil and behavioral disturbances in patients with Alzheimer’s disease. Am J Geriatr Psychiatry 2000; 8: 134–40PubMed
19.
Matthews HP, Korbey J, Wilkinson DG, et al. Donepezil in Alzheimer’s disease: eighteen month results from Southampton Memory Clinic. Int J Geriatr Psychiatry 2000; 15: 713–20PubMedCrossRef
20.
Shea C, MacKnight C, Rockwood K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 1998; 10: 229–38PubMedCrossRef
21.
Fergusson E, Howard R. Donepezil for the treatment of psychosis in dementia with Lewy bodies. Int J Geriatr Psychiatry 2000; 15: 280–1PubMedCrossRef
22.
Weiner MF, Martin-Cook K, Foster BM, et al. Effects of donepezil on emotional/behavioral symptoms in Alzheimer’s disease patients. J Clin Psychiatry 2000; 61: 487–92PubMedCrossRef
23.
Kaufer D, Cummings JL, Christine D. Differential neuropsychiatric symptom responses to tacrine in Alzheimer’s disease: relationship to dementia severity. J Neuropsychiatry Clin Neurosci 1998; 10: 55–63PubMed
24.
McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031–6PubMedCrossRef
25.
Kaufer D. Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer’s disease. Dement Geriatr Cogn Disord 1998; 9: 8–14PubMedCrossRef
26.
Helms PM. Efficacy of antipsychotics in the treatment of the behavioral complications of dementia: a review of the literature. J Am Geriatr Soc 1985; 33: 206–9PubMed
27.
Lanctot KL, Best TS, Mittmann N, et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 1998; 59: 550–61PubMedCrossRef
28.
Risse SC, Barnes R. Pharmacologic treatment of agitation associated with dementia. J Am Geriatr Soc 1986; 34: 368–76PubMed
29.
Raskind MA, Risse SC, Lampe TH. Dementia and antipsychotic drugs. J Clin Psychiatry 1987; 48Suppl. 5: 16–8PubMed
30.
Devanand DP, Sackeim HA, Mayeux R. Psychosis, behavioral disturbance, and the use of neuroleptics in dementia. Compr Psychiatry 1988; 29(4): 387–401PubMedCrossRef
31.
Small GW. Psychopharmacological treatment of elderly demented patients. J Clin Psychiatry 1988; 49 Suppl.: 16–8
32.
Peto R, Collins R, Gray R. Large-scale randomized evidence: large, simple trials and overviews of trials. J Clin Epidemiol 1995; 48: 23–40PubMedCrossRef
33.
Jeste DV, Finkel SI. Psychosis of Alzheimer’s disease and related dementias: diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry 2000; 8: 29–34PubMedCrossRef
34.
Schneider LS. Do we need a meta-analysis update on antipsychotic treatment of behavioral and psychological symptoms of dementia? Int Psychogeriatr 2000; 12: 305–11CrossRef
35.
Rummans TA, Lauterbach EC, Coffey CE, et al. Pharmacologic efficacy in neuropsychiatry: a review of placebo-controlled treatment trials. J Neuropsychiatry Clin Neurosci 1999; 11: 176–89PubMed
36.
Sugerman AA, Williams BH, Adlerstein AM. Haloperidol in the psychiatric disorders of old age. Am J Psychiatry 1964; 120: 1190–2PubMed
37.
Smith GR, Taylor CW, Linkous P. Haloperidol versus thioridazine for the treatment of psychogeriatric patients: a double-blind clinical trial. Psychosomatics 1974; 15: 134–8
38.
Cowley LM, Glen RS. Double-blind study of thioridazine and haloperidol in geriatric patients with a psychosis associated with organic brain syndrome. J Clin Psychiatry 1979; 40: 411–9PubMed
39.
Gotestam KT, Ljunghall S, Olsson B. A double-blind comparison of the effects of haloperidol and cis(Z)-clopenthixol in senile dementia. Acta Psychiatr Scand 1981; 294: 46–53
40.
Petrie WM, Ban TA, Berney S, et al. Loxapine in psychogeriatrics: a placebo- and standard-controlled clinical investigation. J Clin Psychopharmacol 1982; 2: 122–6PubMedCrossRef
41.
Lovett WC, Stokes DK, Taylor LB, et al. Management of behavioral symptoms in disturbed elderly patients: comparison of trifluoperazine and haloperidol. J Clin Psychiatry 1987; 48: 234–6PubMed
42.
Tune LE, Steele C, Cooper T. Neuroleptic drugs in the management of behavioral symptoms of Alzheimer’s disease. Psychiatr Clin North Am 1991; 14: 353–73PubMed
43.
Devanand DP, Cooper T, Sackeim HA, et al. Low dose oral haloperidol and blood levels in Alzheimer’s disease: a preliminary study. Psychopharmacol Bull 1992; 28: 169–73PubMed
44.
Carlyle W, Ancill RJ, Sheldon L. Aggression in the demented patient: a double-blind study of loxapine versus haloperidol. Int Clin Psychopharmacol 1993; 8: 103–8PubMedCrossRef
45.
Dysken MW, Johnson SB, Holden L, et al. Haloperidol concentrations in patients with Alzheimer’s dementia. Am J Geriatr Psychiatry 1994; 2: 124–33
46.
Cantillon M, Brunswick R, Molina D, et al. Buspirone vs haloperidol: a double-blind trial for agitation in a nursing home population with Alzheimer’s disease. Am J Geriatr Psychiatry 1996; 4: 263–7CrossRef
47.
Kinback K, Gierz M. Pharmacological control of behavioral problems in advanced dementias: an open study [abstract]. Am J Geriatr Psychiatry 1996; 4: 368
48.
Auchus AP, Bissey-Black C. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 1997; 9: 591–3PubMed
49.
Caligiuri MP, Rockwell E, Jeste DV. Extrapyramidal side effects in patients with Alzheimer’s disease treated with low-dose neuroleptic medication. Am J Geriatr Psychiatry 1998; 6: 75–82PubMed
50.
Devanand DP, Marder K, Michaels KS, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer’s disease. Am J Psychiatry 1998; 155: 1512–20PubMed
51.
Hamilton LD, Bennett JL. Acetophenazine for hyperactive geriatric patients. Geriatrics 1962; 17: 596–601PubMed
52.
Abse DW, Dahlstrom WG. The value of chemotherapy in senile mental disturbances -controlled comparison of chlorpromazine, reserpine-pipradrol, and opium. JAMA 1960; 2036–42
53.
Barton R, Hurst L. Unnecessary use of tranquillizers in elderly patients. Br J Psychiatry 1966; 112: 989–90PubMedCrossRef
54.
Hamilton LD, Bennett JL. The use of trifluoperazine in geriatric patients with chronic brain syndrome. J Am Geriatr Soc 1962; 10: 140–7PubMed
55.
Altman H, Mehta D, Evenson RC, et al. Behavioral effects of drug therapy on psychogeriatric inpatients: chlorpromazine and thioridazine. J Am Geriatr Soc 1973; 21: 241–8PubMed
56.
Goldstein SE, Birnbom F. Piperacetazine versus thioridazine in the treatment of organic brain disease: A controlled double-blind study. J Am Geriatr Soc 1976; 24: 355–8PubMed
57.
Barnes R, Veith R, Okimoto J, et al. Efficacy of antipsychotic medications in behaviorally disturbed dementia patients. Am J Psychiatry 1982; 139: 1170–4PubMed
58.
Rada RT, Kellner R. Thiothixene in the treatment of geriatric patients with chronic organic brain syndrome. J Am Geriatr Soc 1976; 24: 105–7PubMed
59.
Finkel SI, Lyons JS, Anderson RL, et al. A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients. Int J Geriatr Psychiatry 1995; 10: 129–36CrossRef
60.
Sweet RA, Pollock BG, Mulsant BH, et al. Association of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report. Biol Psychiatry 1997; 42: 1016–23PubMedCrossRef
61.
Nygaard HA, Bakke K, Brudvik E, et al. Dosing of neuroleptics in elderly demented patients with aggressive and agitated behaviour: a double-blind study with zuclopenthixol. Curr Med Res Opin 1994; 13: 222–32PubMedCrossRef
62.
Gutzmann H, Kuhl KP, Kanowski S, et al. Measuring the efficacy of psychopharmacological treatment of psychomotoric restlessness in dementia: clinical evaluation of tiapride. Pharmacopsychiatry 1997; 30: 6–11PubMedCrossRef
63.
Robertsson B, Karlsson I, Eriksson L, et al. An atypical neuroleptic drug in the treatment of behavioral disturbances and psychotic symptoms in elderly people. Dementia 1996; 7: 142–6PubMed
64.
Kodjian A, Barriaga C, Turcot G, et al. Double-blind study of pimozide in senile dementia patients. Curr Ther Res Clin Exp 1986; 40: 694–701
65.
Prado N, Kramerginsberg E, Kremen N, et al. Open-label risperidone in dementia with agitation/psychosis [abstract]. Am J Geriatr Psychiatry 1996; 4: 376
66.
Frenchman IB, Prince T. Clinical experience with risperidone, haloperidol, and thioridazine for dementia-associated behavioral disturbances. Int Psychogeriatr 1997; 9: 431–5PubMedCrossRef
67.
Lavretsky H, Sultzer D. A structured trial of risperidone for the treatment of agitation in dementia. Am J Psychiatry 1998; 6: 127–35
68.
Herrmann N, Rivard MF, Flynn M, et al. Risperidone for the treatment of behavioral disturbances in dementia: a case series. J Neuropsychiatry Clin Neurosci 1998; 10: 220–3PubMed
69.
DeDeyn P, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53: 946–55CrossRef
70.
Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trail. J Clin Psychiatry 1999; 60: 107–15PubMedCrossRef
71.
Satterlee WG, Reams SG, Burns PR, et al. A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer’s disease patients. Psychopharmacol Bull 1995; 31: 534
72.
Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind randomized, placebo-controlled trial. Arch Gen Psychiatry 2000; 10: 968–76CrossRef
73.
McManus DQ, Arvanitis LA, Kowalcyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. J Clin Psychiatry 1999; 60: 292–8PubMedCrossRef
74.
Schneider L, Yeung P, Sweitzer D, et al. Quetiapine mayreduce hostility in patients with psychoses related to Alzheimer’s disease. Schizophr Res 1999; 36: 295–6
75.
Tariot PN, Erb R, Leibovici A, et al. Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. J Am Geriatr Soc 1994; 42: 1160–6PubMed
76.
Lemke MR. Effect of carbamazepine on agitation in Alzheimer’s inpatients refractory to neuroleptics. J Clin Psychiatry 1995; 56: 354–7PubMed
77.
Holm A, Johnson L, Michel M. Divalproex sodium in the treatment in behavioral dysfunction in elderly dementia patients [abstract]. Am J Geriatr Psychiatry 1996; 4: 386
78.
Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60: 107–15PubMedCrossRef
79.
Schneider LS, Tariot PN, Lyketsos CG, et al. National Institute of Mental Health -Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE): Alzheimer’s disease trial methodology. Am J Geriatr Psychiatry 2001; 9: 346–60PubMed
80.
Tariot PN, Blazina L. The psychopathology of dementia. In: Morriss JC, editor. Handbook of dementing illnesses. New York: Marcel Dekker, 1993: 461–75
81.
Cohen-Mansfield J, Billig N. Agitated behaviors in the elderly. I. A conceptual review. J Am Geriatr Soc 1986; 34: 711–21PubMed
82.
Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer Association, and the American Geriatrics Society. JAMA 1997; 278: 1363–71PubMedCrossRef
83.
Harwood DG, Sultzer DL, Wheatley MV. Impaired insight in Alzheimer disease: association with cognitive deficits, psychiatric symptoms, and behavioral disturbances. Neuropsychiatry Neuropsychol Behav Neurol 2000; 13: 83–8PubMed
84.
Wragg R, Jeste DV. Overview of depression and psychosis in Alzheimer’s disease. Am J Psychiatry 1989; 146: 577–87PubMed
85.
Laughren T. A regulatory perspective on psychiatric syndromes in Alzheimer disease. Am J Geriatr Psychiatry 2001; 9: 340–5PubMed
86.
Schneider LS. Pharmacologic management of psychosis in dementia. J Clin Psychiatry 1999; 60: 54–60PubMed
87.
Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary and critique. Am J Geriatr Psychiatry 2001; 9: 361–81PubMed
88.
McEvoy GK, Litvak K, Welsh OH, et al. AHFS Drug Information. Bethesda (MD): ASHP, 2000
89.
Tune LE. Serum anticholinergic activity levels and delirium in the elderly. Semin Clin Neuropsychiatry 2000; 5: 149–53PubMed
90.
91.
Maixner SM, Mellow AM, Tandon R. The efficacy, safety, and tolerability of antispychotics in the elderly. J Clin Psychiatry 1999; 60: 29–41PubMedCrossRef
92.
Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000; 157: 1150–5PubMedCrossRef
93.
Beasley CM, Dellva MA, Tamura RN, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999; 174: 23–30PubMedCrossRef
94.
Tran PV, Dellva MA, Tollefson GD, et al. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997; 58: 205–11PubMedCrossRef
95.
Arvanitis LA, Miller GB. Multiple fixed doses of quetiapine in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 2000; 42: 233–46CrossRef
96.
Verhaeverbeke I, Mets T. Drug-induced orthostatic hypotension in the elderly: avoiding its onset. Drug Saf 1997; 17: 105–18PubMedCrossRef
97.
Paulsen JS, Heaton RK, Sadek JR, et al. The nature of learning and memory impairments in schizophrenia. J Int Neuropsychol Soc 1995; 1: 88–99PubMedCrossRef
98.
Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 1989; 98: 367–80PubMedCrossRef
99.
Jeste DV, Lohr JB, Eastham JH, et al. Adverse neurobiological effects of long-term use of neuroleptics: human and animal studies. J Psychiatr Res 1998; 32: 201–14PubMedCrossRef
100.
McShane R, Keene J, Gedling K, et al. Do neuroleptic drugs hasten cognitive decline in dementia: prospective study with necropsy follow up. BMJ 1997; 314: 266–70PubMedCrossRef
101.
Tobiansky R, Blanchard M. Do neuroleptic drugs hasten cognitive decline in dementia? BMJ 1997; 314: 411–2
102.
Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25: 233–55PubMedCrossRef
103.
Gallhofer B, Bauer U, Lis S, et al. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 1996; 6Suppl. 2: S13–20PubMedCrossRef
104.
Harvey PD, Keefe RSE. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001; 158: 176–84PubMedCrossRef
105.
Strauss ME. Effects of anticholinergic medication on memory in schizophrenia. Schizophr Res 1990; 3: 17–9CrossRef
106.
Goldberg TE, Weinberger DR. The effects of clozapine on neurocognition: an overview. J Clin Psychiatry 1994; 55Suppl. B: 88–90PubMed
107.
Velligan DI, Newcomer J, Pultz J, et al. Does cognitive function improve with quetiapine in comparison to haloperidol. Schizophr Res 2002; 53: 239–48PubMedCrossRef
108.
Goldberg RJ, Goldberg J. Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience. Int Psychogeriatr 1997; 9: 65–8PubMedCrossRef
109.
Finkel SI. Managing the behavioral and psychological signs and symptoms of dementia. Int Clin Psychopharmacol 1997; 12Suppl. 4: S25–8PubMedCrossRef
110.
Sweet RA, Pollock BG. New atypical antipsychotics. Experience and utility in the elderly. Drugs Aging 1998; 12: 115–27PubMedCrossRef
111.
Workman RH. The use of risperidone for psychosis and agitation in demented patients with parkinson’s disease. J Neuropsychiatry Clin Neurosci 1997; 9: 594–7PubMed
112.
Tandon R. Antipsychotic agents. In: Quitkin FM, Adams DC, Bowden CL, editors. Current psychotherapeutic drugs. 2nd ed. Philadelphia (PA): Current Medicine Inc., 1998: 120–54
113.
Frankenburg FR, Zanarini MC, Kando J, et al. Clozapine and body mass change. Biol Psychiatry 1998; 43: 520–4PubMedCrossRef
114.
Masand PS, Gupta S. Long-term adverse effects of novel antipsychotics. J Psychiatric Pract 2000; 6: 299–309CrossRef
115.
Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44: 778–83PubMedCrossRef
116.
Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparisons of weight gain liabilities. J Clin Psychiatry 1999; 60: 358–63PubMedCrossRef
117.
Umbricht DSG, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry 1994; 59: 157–60
118.
Kraus T, Haack M, Schuld A, et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999; 156: 312–4PubMed
119.
Bustillo J, Buchanan R, Irish D, et al. Differential effect of clozapine on weight: a controlled study. Am J Psychiatry 1996; 153: 817–9PubMed
120.
Dekker JM, Schouten EG, Klootwijk P, et al. Association between QT interval and coronary heart disease in middle-aged and elderly men. Circulation 1994; 90: 779–85PubMedCrossRef
121.
Welch R, Chue P. Antipsychotic agents and QT changes. J Psychiatry Neurosci 2000; 25: 154–60PubMed
122.
Czekalla J, Kollack-Walker S, Beasley CM. Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. J Clin Psychiatry 2001; 62: 35–40PubMedCrossRef
123.
Grad R. Benzodiazepines for insomnia in community-dwelling elderly: a review of benefit and risk. J Fam Pract 1995; 41: 473–81PubMed
124.
Burke JR, Morgenlander JC. Managing common behavioral problems in dementia. Postgrad Med 1999; 106: 131–40PubMed
125.
Herrmann N. Valproic acid treatment of agitation in dementia. Can J Psychiatry 1998; 43: 69–72PubMed
126.
Porsteinsson AP, Tariot PN, Erb R, et al. An open trial of valproate for agitation in geriatric neuropsychiatric disorder. Am J Geriatr Psychiatry 1997; 5: 344–51PubMedCrossRef
127.
Tariot PN, Schneider LS, Katz IR. Anticonvulsant and other non-neuroleptic treatment of agitation in dementia. J Geriatr Psychiatry Neurol 1995; 8: 500–12CrossRef
128.
Qizibash N, Whitehead A, Higgins J, et al. Cholinesterase inhibition for Alzheimer disease. JAMA 1998; 280: 1777–82CrossRef
129.
Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54: 2269–76PubMedCrossRef
Metadata
Title
Pharmacological Treatment of Psychosis and Agitation in Elderly Patients with Dementia
Four Decades of Experience
Authors
Sandra S. Kindermann
Christian R. Dolder
Anne Bailey
Ira R. Katz
Professor Dilip V. Jeste
Publication date
01-04-2002
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 4/2002
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200219040-00002

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits